Earnings Feed
Start Free
Kymera Therapeutics, Inc.·4

Mar 25, 5:15 PM ET

Chadwick Jeremy G 4

Research Summary

AI-generated summary

Updated

Kymera (KYMR) COO Jeremy Chadwick Exercises Options & Sells Shares

What Happened

  • Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics (KYMR), exercised stock options and sold shares in transactions on March 23 and March 25, 2026. He exercised a total of 109,127 shares (84,400 on 3/23 and 24,727 on 3/25) at an exercise price of $29.64, paying about $3.23 million in aggregate.
  • Following the exercises, Chadwick disposed of multiple blocks of shares in the open market: a total of ~115,977 shares across several trades (major blocks on 3/23 and 3/25) for aggregate gross proceeds of about $9.05 million. The activity appears routine (exercises followed by sales), rather than an outright purchase.

Key Details

  • Transaction dates and prices:
    • 2026-03-23: Exercised 84,400 shares @ $29.64 (cost ≈ $2,501,616); sold multiple lots totaling 91,250 shares at weighted-average prices between ~$75.96–$80.00 (combined proceeds ≈ $7.06M).
    • 2026-03-25: Exercised 24,727 shares @ $29.64 (cost ≈ $732,908); sold 24,727 shares @ $80.26 (proceeds ≈ $1.98M).
    • Aggregate exercised = 109,127 shares (exercise cost ≈ $3.23M). Aggregate sold = ~115,977 shares (gross proceeds ≈ $9.05M).
  • Shares owned after transaction: not provided in the excerpt you supplied.
  • Footnotes / notable items:
    • Transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 (F1).
    • Several sales prices are reported as weighted averages covering price ranges (F2–F6). Vesting terms for the option grant are noted (25% vested May 22, 2024; remainder vest monthly over 36 months) (F7).
    • Derivative entries showing $0 reflect conversion/exercise of options (standard reporting notation).
  • Filing timeliness: Form filed March 25, 2026 for trades on March 23 and March 25 — not indicated as late in the provided data.

Context

  • These transactions are classic option exercises followed by open-market sales. While exercises indicate the insider converted options into shares, the immediate sales mean this is not a fresh personal purchase that would signal increased insider ownership. The presence of a 10b5-1 plan suggests trades were preplanned and potentially automated.